|
|
|
|
Infosys Technologies And Elan Pharmaceuticals Apply Co-Creation Model To Transform Discovery Research
Fremont, CA /PRNewswire/ -- Infosys Technologies Limited (Nasdaq: INFY) today announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, Inc (NYSE: ELN), a leading biotechnology company, to accelerate discovery...
|
|
|
GSK Launches New Specialist Unit To Research And Develop Medicines For Rare Diseases
GSK recently announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases.Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a...
|
|
|
Entelos Granted Patent For Innovative Diagnostic Capability In Obesity, Diabetes
Entelos,Inc., a simulation and modeling companyfocused on human health, announced today that the U.S.Patent and Trademark Office has granted U.S. Patent No. 7,654,955 entitled 'Apparatus and Methods for Assessing Metabolic Substrate Utilization' to the...
|
|
|
Lannett To Submit New Drug Application For Morphine Sulfate Products
Lannett Company, Inc.(NYSE AMEX: LCI) today announced plans to submit its New Drug Application (NDA) for its Morphine Sulfate products to the U.S. Food and Drug Administration (FDA) at the end of the month. The company expects the FDA to review its...
|
|
|
The Colorado Institute For Drug, Device And Diagnostic Development Launches With A Statewide 'Call For Proposa
Aurora, CO /PRNewswire/ - The Colorado Institute for Drug, Device and Diagnostic Development (CID4) launches this month with a statewide 'Call for Proposals' from Colorado life science technologies in need of funding and active management.The announcement is...
|
|
|
Medical Research Council Technology's Centre For Therapeutics Discovery Opens Its First 'Call For Targets' In
London /PRNewswire/ - A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today.The MRCT Centre for Therapeutics...
|
|
|
Vantia TherapeuticsEUR Lead Candidate VA106483 Enters Phase IIb Trial For Nocturia
Southampton, UK - Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for...
|
|
|
Kantar Health And ImpactRx Launch CancerMPact Monthly Drugs And Regimens For Oncology Business Decisions
New York and Mount Laurel, NJ /PRNewswire/ - Kantar Health, a leading healthcare-focused consultancy and oncology center of excellence, and ImpactRx, a pioneer in tracking and evaluating pharmaceutical promotion on the prescribing behavior of physicians,...
|
|
|
Advanced Cancer Therapeutics Funds Brown Cancer Center Research Scientist to Accelerate Identification Of Clin
Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr.John Trent, Associate...
|
|
|
Pall Corporation Introduces The PallSep Biotech Filtration System For Difficult-To-Process Biotechnology Feed
Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, has introduced the PallSep Biotech system for the gentle separation of target molecules from complex biotechnology process fluids.The new system utilizes vibrating...
|
